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The follicle-stimulating hormone (FSH) is involved in the regulation of 
reproduction, by acting through a G protein-coupled receptor (GPCR) on the surface of 
target cells. Like most of the GPCRs, not much is known about the structure of the 
follicle-stimulating hormone receptor (FSHR). It is relatively difficult to purify the 
FSHR protein from gonadal tissues, due to its low abundance on its native cells, and 
therefore, to study its structure. For these reasons it is necessary to come up with a 
strategy that allows the production of large quantities of protein in order to use it in 
studies to obtain detailed structural information on full-length human FSHR. 
Via polymerase chain reactions, site-directed mutagenesis and other molecular 
biological methods, we were able to construct mutated receptors with different signal 
sequences and different tags, including the last fifteen amino acids of human rhodopsin 
which allow the receptor to be expressed on retinal rod cells of zebrafish. Mutations 
were designed in a manner that the receptor becomes inactive, i.e. incapable of signal 
transduction but still expressed at cell surface. The receptor constructs were first tested 
in human embryonic kidney cells (HEK 293-T) and their inserts will be used for 
transgenetic studies on zebrafish in the future. 
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A hormona estimulante do folículo (FSH) está envolvida na regulação da 
reprodução, actuando através de um receptor acoplado a proteínas G (GPCR) localizado 
à superfície das células alvo. Tal como a maioria dos GPCRs, pouco se sabe acerca da 
estrutura do receptor da hormona estimulante do folículo (FSHR). Este receptor é 
relativamente difícil de purificar de tecidos gonadais, devido à pouca abundância com 
que se encontra nas suas células nativas, e, portanto, de estudar a sua estrutura. Por estas 
razões é necessário criar uma estratégia que permita a produção de grandes quantidades 
de proteína de modo a poder usá-la em estudos dirigidos à obtenção de informação 
detalhada da estrutura completa do FSHR. 
Através de reacções em cadeia da polimerase, mutagénese dirigida e outros 
métodos biomoleculares foi possível construir receptores mutantes com diferentes 
sequências sinal e diferentes tags, incluindo os últimos quinze aminoácidos da 
rodopsina humana que permitem a expressão do receptor em bastonetes da retina de 
peixe zebra. As mutações foram criadas de modo a que o receptor se torne inactivo, i.e. 
incapaz de realizar transdução de sinal mas que ainda é expresso à superfície da célula. 
Os receptores foram primeiro testados em células embriónicas humanas do rim (HEK 
293-T) e os insertos serão usados em estudos de transgénese em peixe zebra. 
 
Palavras-chave: Receptores acoplados a proteínas G, receptor da hormona estimulante 















7-TM = 7-transmembrane domain 
ATP = Adenosine triphosphate 
cAMP = Cyclic adenosine monophosphate 
CCR = C-terminal cysteine-rich 
cDNA = Complementary deoxyribonucleic acid 
CG = Chorionic gonadotropin 
DMEM = Dulbecco’s modified Eagle’s medium 
DNA = Deoxyribonucleic acid 
(d)dNTPs = (di)deoxyribonucleotide triphophates 
EC50 = Effect concentration 50% 
ECD = Extracellular domain 
EDTA = Ethylene-diamine-tetra-acetic acid 
ELx = Extracellular loop n.º x 
ELISA = Enzyme- linked immunosorbent assay 
FSH = Follicle-stimulating hormone 
FSHR = Follicle-stimulating hormone receptor 
FSHRHB = hormone-binding domain of the human follicle-stimulating hormone 
receptor 
GDP = Guanosine diphosphate 
GFP = Green fluorescent protein 
GnRH = Gonadotropin-releasing hormone 
GnRHR = Gonadotropin-releasing hormone receptor 
GPCR = G protein-coupled receptor 
GpH = Glycoprotein hormone 
GpHR = Glycoprotein hormone receptor 
GTP = Guanosine triphosphate 
HEK = Human embryonic kidney 
hFSH = Human follicle-stimulating hormone 
hFSHR = Human follicle-stimulating hormone receptor 
LB = Luria-Bertani 
LH = Luteinizing hormone 
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LHR = Luteinizing hormone receptor 
LRRs = Leucine-rich repeats 
MCS = Multiple cloning site 
mRNA = Messenger ribonucleic acid 
NCR = N-terminal cysteine rich 
NTED = N-terminal exodomain 
ONPG = o-nitrophenyl-β-D-galactopyranoside 
PBS = Phosphate saline buffer 
PCR = Polymerase chain reaction 
PRL = Prolactin 
PEI = Polyethylenimine 
RHO15 = Last 15 amino acids of human rhodopsin 
ROS = Rod outer segment 
TMx = Transmembrane domain n.º x 
TSH = Thyroid-stimulating hormone 
TSHR = Thyroid-stimulating hormone receptor 
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1.1 The endocrinology of reproduction 
 
In mammals, reproduction is controlled by the pituitary hormones – luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH). The hypothalamus secretes 
gonadotropin-releasing hormone (GnRH), which then reaches the pituitary, through the 
hypothalamo-pituitary portal vessels, where it stimulates the release of the 
gonadotropins FSH and LH. These two hormones will then act on either the ovaries in 
females or the testes in males, regulating the two most important functions of the 
gonads: the production of gametes and the secretion of sex hormones (Figure 1). 
(Vander, Sherman and Luciano, 2001) 
 
 
Figure 1: Schematic representation of the control of reproduction in both males and females. 
 
FSH and LH belong to the glycoprotein hormone family, which also includes 
chorionic gonadotropin (CG) and thyroid-stimulating hormone (TSH). These hormones 
are disulphide-rich heterodimers consisting of a common α-subunit and a unique β-
subunit, within a given species, that are non-covalently associated. They act on target 
cell surfaces by binding to specific G protein-coupled receptors (FSH and TSH bind to 
FSHR and TSHR, respectively; LH and CG bind to LHR), which contain an 
extracellular domain with multiple leucine-rich repeats and a transmembrane domain 
consisting of seven helices (Fan
 
& Hendrickson, 2005). 
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1.2 The G protein-coupled receptors 
 
G protein-coupled receptors (GPCRs) are the largest family of integral 
membrane proteins and are found in most eukaryotic organisms, where they modulate a 
wide variety of biological processes, through diverse extracellular stimuli. In fact, 
almost all known physiological processes are regulated by GPCRs, which means that 
various dysfunctions or diseases may be caused by defects in the signaling pathways. 
Therefore, a large fraction of drugs exert their action via interaction with these 
receptors. However, less than 10% of all known GPCRs are targeted which makes it 
very important to understand them. This is yet a difficult task since there is a serious 
lack of structural and functional data (Tao, 2006; McCusker et al., 2007 and Park et al., 
2008). 
 
 There are several factors that make it difficult to obtain high resolution 
diffraction data for GPCRs in order to solve their structures. One of those factors is that 
GPCRs are usually expressed at very low levels in their native cells and it is very 
difficult to produce high amounts of recombinant receptor protein. Also the purification 
step(s) present(s) some difficulties because detergents need to be used to solubilize the 
GPCRs, reducing the yield of the procedure. In addition, degradation can occur, 
affecting the stability of the purified receptor. Furthermore, GPCRs have flexible 
domains that reduce the contact sites needed for crystal formation. Another factor is that 
many GPCRs exhibit basal activity, i.e. they can be in an activated state without being 
stimulated by an agonist, which has been associated with structural instability 
(Lundstrom et al., 2006; Rasmussen et al., 2007). 
 
GPCRs, like all proteins, have their mRNA being transcribed in the nucleus and, 
then, at the ribosome, the polypeptide sequence is synthesized. In the endoplasmic 
reticulum (ER) immature carbohydrates are added onto the polypeptides, forming 
glycoproteins. The maturation of the carbohydrates occurs in the Golgi apparatus, after 
initial folding, and the receptor is transported to the cell surface (Tao, 2006).  
Like the name says, GPCRs are coupled to a G protein, which is composed of 
three protein subunits, α, β, and γ. When the receptor is activated by a ligand, there is a 
conformational change in the receptor that leads a conformational change in the G 
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protein that leads to the conversion of GDP to GTP on the Gα subunit, causing the latter 
to be dissociated from Gβγ. One of the possible signaling pathways is initiated by the 
activation of adenylil cyclase by the Gα, if this protein is a so-called stimulatory Gα 
(Gαs), by catalyzing the synthesis of cyclic AMP (cAMP) from ATP (Figure 2) (Alberts 
et al., 2002). 
Activated GPCRs can be desensitized by either phosphorylation or 
internalization. When internalized, they can be recycled back to the cell surface, where 




Figure 2: Hormonal activation of adenylyl cyclase. Binding of hormone promotes the interaction of the 
receptor with a G protein. The activated G protein α subunit then dissociates from the receptor 




1.2.1 The G protein-coupled receptors structure 
 
According to sequence homology, the GPCRs can be divided into classes: class 
A, or rhodopsin/β2 adrenergic receptor-like GPCRs; class B, or receptors related to the 
glucagon receptor; class C, which corresponds to receptors related to the metabotropic 
neurotransmitter receptors and two more minor classes. One feature that all these 
classes have in common is a transmembrane domain consisting of seven α-helices 
connected by three extracellular and three intracellular loops, with the amino terminus 
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located on the extracellular side and the carboxy terminus in the cytoplasm (Figure 3) 




Figure 3: Schematic representation of the structure of a GPCR. This scheme represents a class A, or 
rhodopsin/β2 adrenergic receptor-like GPCR. These receptors contain some highly conserved 
residues, depicted by the black letters in white circles. The white letters in black circles show a 
disulfide bridge that connects the second (EL2) and third extracellular loop (EL3) and a 
palmitoylated cysteine in the carboxy-terminal tail that forms a putative fourth intracellular 





The first crystal structure available for a GPCR was the one of rhodopsin 
(Palczewski et al, 2000). This receptor responds to light by starting the signal 
transduction that induces vision. It can be isolated from retina, where it exists in large 
quantities, and it is very stable in the absence of light, which makes it relatively easy to 
purify and, therefore, to be studied.  
 
Previous studies involving electron microscopy and cryoelectron microscopy 
(Schertler, 1993) had showed, two-dimensionally, the presence of the 7-TM domain 
(Figure 4) and, through homology-modelling studies, provided structural information 
about other GPCRs. These studies together with the information of the high resolution 
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structure obtained by X-ray crystallography (Figure 5) can help understanding how 
ligands bind to GPCRs and how the signaling pathways proceed since it contains highly 




Figure 4: Two-dimensional model of bovine rhodopsin. Residues shown in black circles indicate the 
position of mutations associated with retinitis pigmentosa. In rhodopsin, extracellular 





Figure 5: Crystal structure of bovine rhodopsin. (a) I to VII correspond to the transmembrane helices; 
VIII is a short helix found between H-VII and the C-tail; C-I, C-II and C-III are the 
intracellular loops; C-tail is the cytoplasmic tail; E-I, E-II and E-III are the extracellular loops 
and N-tail is the extracellular tail. Cys322 and Cys323 are palmitoylated and anchor the C-tail to 
the membrane. (b) Most conserved residues among G-protein-coupled receptor, including 
Cys110 and Cys187 that form a disulfide bridge between H-III and E-II, and Cys322 and Cys323 
that are palmitoylated and anchor the C-tail to the membrane (Okada et al., 2001). 
 
 
The bovine rhodopsin protein shown in Figures 4 and 5 is 348 amino acid long, 
which is an intermediate number amongst GPCRs. It is expected that the lengths of the 
transmembrane helices and of the extracellular loops are approximately the same for 
these receptors. Since the majority of the conserved residues are found in that area, it 
means that the other areas are responsible for the ligand specificity of each receptor 
(Palczewski et al., 2000). 
Rhodopsin is expressed in retinal rod photoreceptor cells (Figure 6). These are 
specialized neurons that recognize the presence of light by means of the rhodopsin 
protein, which undergoes conformational changes leading to phototransduction. They 
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are highly differentiated cells consisting of a synapse or cell body, an inner segment and 
an outer segment (ROS). The inner segment contains the mitochondria, the ER and the 
Golgi apparatus and its where the rhodopsin is synthesized. The molecules are then 
transported to the ROS in post-Golgi membrane vesicles, where they are incorporated 
and accumulated in the ROS disk membranes (Filipek et al., 2003; Tai et al., 1999 and 




Figure 6: Morphology and characteristics of a highly differentiated vertebrate rod photoreceptor cell 
(Zhang et al., 2005). 
 
As said before, defects on GPCRs may cause several diseases and so rhodopsin 
mutants have been shown to be involved in eye diseases such as retinitis pigmentosa. 
Mutations in the C-terminal tail impair the trafficking of rhodopsin to the ROS, 
meaning that this is the region that contains the necessary signals for proper sorting and 







1.2.3 Glycoprotein hormone receptors and their general structure 
 
Within the class A of GPCRs, there is a subfamily consisting of the glycoprotein 
hormone receptors (GpHR) that includes the FSHR, the LHR and the TSHR. Like all 
GPCRs, these receptors have a seven transmembrane (7-TM) α-helical structure and a G 
protein coupled on their cytoplasmic surface, but unlike the rest of the rhodopsin-like 
receptors they have a large N-terminal exodomain (NTED) with multiple leucine-rich 
repeats (LRR) (Figure 7) (Fan
 
and Hendrickson, 2005; Vassart et al., 2004 and Durme 




Figure 7: Schematic representation of the human FSHR protein, illustrating the NTED, the 7-TM helices 
and the C-terminal intracellular tail. The β-strand in each of the consecutive LRRs is indicated 
by an arrow, and the consecutive hydrophobic residues that form the hydrophobic core of the 
LRR domain are indicated by circles with a grey background. Putative N-linked carbohydrates 
are indicated by a “Y”. The Cys residues present in the NCR and CCR subdomains are 
indicated by circles with a black background. The disulfide bond between the conserved Cys 
residues in EL1 and 2 is indicated by a black line. The cell membrane is represented by two 
black bars, and a palmitoylated Cys residue anchoring the C-terminal tail to the cell membrane 
is indicated by a grey zigzagging bar (Bogerd et al, 2005). 
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The three-dimensional structure of the porcine ribonuclease inhibitor (Kobe and 
Deisenhofer, 1993) helped to generate structural models of the NTED of the GpHRs, 
showing that the exodomain is composed of an N-terminal cysteine-rich cluster (NCR), 
nine imperfect LRR motifs and a C-terminal cysteine-rich cluster (CCR) (Figure 8a).  
 The LRR motifs consist of 20-25 amino acids that form a short β-strand and an 
α-helix positioned antiparallel to each other, forming repetitive right-handed hairpin-
like units that are connected by short loops (Figure 8b). The β-strands make a concave 
inner surface that gives the molecule a horseshoe-shaped structure, where the ligand 
binds. Figure 7c shows a single LRR unit that is composed by seven residues – X1-X2-
L-X3-L-X4-X5 – where X is any amino acid and L can be leucine, isoleucine or other 
hydrophobic residues. The side chains of the L amino acids are directed towards the 
helix and form the hydrophobic core of this structure, giving it stability, whereas the 
side chains of the X residues point outwards, contributing to the hormone-binding 
interface. Therefore, the specificity and high affinity of the GpHRs for their respective 




Figure 8: Schematic representation of the structures composing glycoprotein hormone receptors. (a) 
Two-dimensional representation of the glycoprotein hormone receptors’ NTED, where the 
purple boxes correspond to N-terminal and C-terminal cysteine-rich regions of the ectodomain 
and the green box shows the nine leucine-rich repeats (LRR). (b) Repeats are made of β-
strands (arrows) followed by α-helices (cylinders). (c) Single LRR unit composed by seven 




When the hormone binds to the NTED, some changes not yet known occur in 
the 7-TM domain leading to the exchange of GDP for GTP on the Gα subunit of the G 
protein. This means that the receptor activation and signal transduction through G 
protein is determined by the 7-TM domain (Fan
 
and Hendrickson, 2005). 
 
 
1.2.4 The follicle-stimulating hormone receptor 
 
In 1992, Kelton et al. cloned the human follicle-stimulating hormone receptor 
(FSHR) and found that it has an open reading frame of 2088 nucleotides, encoding for a 
695 amino acid long protein. The first 17 amino acids encode for a hydrophobic signal 
peptide that precedes the N-terminal domain of 349 amino acids. The next 264 amino 
acids correspond to the transmembrane domain which is followed by the intracellular 
cytoplasmic domain (65 amino acids). The full sequence of the FSHR can be found in 
Appendix 6.1 and the schematic representation of its structure is shown in Figure 7. 
 
In 2005, Fan and Hendrickson were able to determine the crystal structure of the 
N-terminal hormone-binding domain of the human follicle-stimulating hormone 
receptor (FSHRHB) bound to the follicle-stimulating hormone (FSH) (Figure 9). In this 
structure, the FSHRHB appears in a truncated form, i.e. NCR and LRR without the CCR, 
meaning that this last portion is not implicated in the binding. In Figure 9b it is possible 
to see that the FSHRHB is shaped as a tube with a slight concave bend, where the FSH 






Figure 9: Crystal structure of human FSH bound to FSHRHB. a) and b) Ribbon diagram of the complex 
structure shown in two views related by a 90° rotation about the vertical axis. FSH α-chains 
and β-chains are in green and cyan, respectively. FSHRHB is in red. The observed N-linked 
carbohydrates at N52 and N78 of FSH-α, N7 and N24 of FSH-β, and N191 of FSHRHB are in 





Inactivating mutations in the FSHR can help understand its physiological role 
and also the functioning of its domains, since some studies revealed that they cause 
ovarian dysgenesis, amenorrhea and infertility in women (Tao, 2006). 
 
The first naturally occurring mutation was found in several Finnish patients with 
primary amenorrhea due to ovarian
 
failure and refers to the substitution of alanine for 
valine in position 189 (Ala
189
Val) in the extracellular domain (ECD) (Aittomäki et al., 
1995). This mutation has been shown to result in a decrease of the binding capacity and, 
consequently, of the signalling response. However, further studies on the cell surface 
expression of the receptor showed that only a weak expression was observed, meaning 
that the receptor is trapped inside the cell. This alanine is part of a highly conserved 




in FSHR) and appears to be of 
extreme importance for folding and trafficking of the receptor (Rannikko et al., 2002). 
Some other mutations in the ECD include Ile
160
Thr (isoleucine → threonine), 
Asn
191
Ile (asparagine → isoleucine), Asp
224














cause the receptor to be retained intracellularly and, as a consequence, reduce the 





a mutant FSHR that has complete loss of function in in vitro
 
studies of receptor activity 
and is unable to bind hormone (Allen et al., 2003). 
 
In the second α-helix of the transmembrane domain (TM2), a mutation of 
alanine on position 419 by a threonine (Ala
419
Thr) allows the receptor to have normal 
ligand-binding affinity and capacity but makes it defective in signalling (Doherty et al., 
2002). Other substitutions in the transmembrane domain include Pro
519
Thr (proline → 
threonine) in EL2, Arg
573
Cys (arginine → cysteine) in IL3 and Leu
601
Val (leucine → 
valine) in EL3: the first results in total loss of function and the other two are expressed 
normally at cell surface but exhibit low signalling. 
 
In summary, the location of the amino acid (Figure 10) is more important than 
its nature since the mutations located in the extracellular domain of the receptor cause a 
defect in targeting the protein to the cell surface, whereas mutations in the 
transmembrane domain impair the signal transduction. 
 
 







Transgenesis is a technique that allows the insertion of foreign DNA into the 
genome of a (model) organism in order to express specific gene products in a controlled 
manner. One such model is the zebrafish (Danio rerio) due to its easy maintenance and 
breeding. Another advantage of this organism is its transparent nature during embryonic 
and larval stages that makes it possible to, for example, observe green fluorescence in 
animals that express the GFP reporter gene (Perkins et al., 2002; Laan et a.l, 2002; 
Kawakami et al., 2004).  
 
The use of transposable elements is one of the most efficient transgenetic 
methods. Discovered by Barbara McClintock in 1950, the transposons are sequences of 
DNA that are integrated in a host genome, without causing enormous DNA 
rearrangements.  
 
Tol2 is a naturally occurring transposable element found in the genome of the 
Japanese medaka fish (Oryzias latipes). This element has been used for transgenesis of 
zebrafish: a plasmid containing the Tol2 element, which lacked part of the transposase 
gene, in combination with the transposase mRNA, which was synthesized in vitro using 
cloned Tol2 cDNA as a template, were co-injected into fertilized eggs. The transposase 
mRNA is then used by the egg to produce the transposase enzyme that catalyzes the 
excision of the vector sequences (i.e. the foreign DNA fragment to be used for 
transgenesis) from the plasmid and its integration into the host genome. The transposon-
mediated DNA insertions can then be transmitted to the next generation through the 





Figure 11: Transposition of the Tol2 transposon vector in zebrafish. A plasmid DNA containing a 
transposon vector (with the GFP gene) is co-injected with the transposase mRNA synthesized 
in vitro. The transposon vector is excised from the plasmid DNA, integrated in the genome 
and transmitted to the F1 generation. GFP is expressed by embryos carrying the insertions 


















2. Material and Methods 
 
2.1 Overall strategy 
 
2.1.1 Part 1 – Construction of hFSHR with different signal sequences and 
different tags. 
 
The general structure of the different hFSHR constructs is represented on Figure 
12 with GPCR being the wild type human FSHR (wt-hFSHR) or the human FSHR with 
a catfish GnRHR C-terminal tail and the last 15 amino acids of the human rhodopsin 
sequence (hFSHR/cf-tail/RHO15). The different signal sequences and different tags are 





Figure 12: Basic scheme of the FSHR constructs. 
 
 
Table 1: Description of the different signal sequences and different tags, according to the construct code, 
where X corresponds to either A (wt-hFSHR) or B (hFSHR/cf-tail/RHO15), giving 22 constructs 
in total. 




















sequence Tag GPCR 
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Using the SignalP 3.0 server (http://www.cbs.dtu.dk/services/SignalP/) it is 
possible to predict the presence and location of signal peptide cleavage sites at the N 
terminus of amino acid sequences from different organisms, based on a combination of 
several artificial neural networks and hidden Markov models. Appendix 6.2 shows the 
prediction results for a prolactin-FLAG sequence. 
 
The constructs with the different tags and the different signal sequences will be 
inserted into the Bgl II/ Bam HI sites of the multiple cloning site (MCS) of the pIRES2-
EGFP vector (Figure 13) where the internal Not I site has been previously knocked out, 




Figure 13: Restriction map and multiple cloning site (MCS) of pIRES2-EGFP Vector. 
 
 
The plasmids will then be ready to be transfected into HEK 293-T cells to check 
for cell surface expression of the receptors through ELISA and to detect ligand-induced 




Not I KO 
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2.1.2 Part 2 – Construction of mutated hFSHRs. 
 
Part 1 will determine which constructs to use next, i.e. the constructs with best 
results for the ligand-induced cAMP production and the cell surface expression. 
On these constructs, site-directed mutagenesis will be performed in order to 
create constructs that are expressed on cell surface but that are deficient in signaling. 
 































2.2 Optmization of FSHR constructs 
 
2.2.1 Polymerase chain reaction 
 
The polymerase chain reaction (PCR) is a technique that allows the production 
of millions of copies of a specific DNA fragment. The reaction normally consists of 25 
to 35 cycles of basic steps where the temperature is shifted between 3 values:  
• the mixture is heated to 94 °C, which is the denaturation temperature, and the 
hydrogen bonds that hold the DNA strands together are broken; 
• then the temperature is lowered to 50-60 °C allowing the annealing of the 
primers to the single-stranded DNA template; 
• finally, in the elongation step, the temperature is raised to 72 °C and this enables 
the Taq DNA polymerase to synthesize new strands complementary to the DNA 
template by attaching at the end of each primer. 
 
One of the most important variables in a PCR reaction is the primer design. The 
melting temperature (Tm) of each primer should be approximately 70 °C and it is used 
to estimate the annealing temperature (5 °C below the lowest, calculated Tm). Also the 
length and the sequence of the primers must be accounted for: they should be at least 22 
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nucleotides long, have a G-C content of 45–60% and their 3’-terminal ends should not 
be complementary to each other and should contain a low G-C content (Brown, 2001 
and Advantage
®
 2 PCR Enzyme System User Manual, Clontech, 2008). 
 
 Construction of hFSHR/cf-tail/RHO15 
 
It is possible to construct a human FSHR with a catfish GnRHR C-terminal tail 
and the last 15 amino acids of human rhodopsin (RHO15) by means of a fusion PCR.  
A PCR was performed on a cfGnRHR/RHO15, in order to obtain only the C-
terminal tail with the RHO15 (B on Figure 14). This portion partially overlaps with the 
hFSHR (A on Figure 14), allowing the two fragments to hybridize in a new PCR 
reaction, where the hybrid is elongated by the polymerase. 
 
 
Figure 14: Example of a fusion PCR (adapted from Strachan and Read, 1999). 
 
 
 Construction of hFSHR with different tags 
 
In order to build constructs of the hFSHR with different tags, the PCR reaction 
mixtures had the composition described in Table 3 and Table 4 shows the primers used 
for the construction of receptors with a FLAG tag. 
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Table 3: Composition of the PCR reaction mixture using an Advantage 2 kit. 
Component Volume (µL) 
H2O 29 
10x Adv2 reaction buffer 5 
10x dNTPs 1 
10 µM Forward primer 2 
10 µM Reverse primer 2 
1 ng/µL hFSHR 10 
50x Adv2 DNA polymerase 1 
 
 
Table 4: Sequence of the primers used to construct receptors with a FLAG tag (the codon sequence for 
the FLAG tag amino acid sequence DYKDDDDV is shown in bold); fw – forward; rv – reverse. 




2916 (rv) 5’-GCTAGGCAGGGAATGAATTCTTGTTCTTGAAATATCT-3’ 
 
 
The reaction conditions were as follows: 
 
Table 5: PCR program used to construct receptors with a FLAG tag. 
Cycles Temperature (°C) Time (s) 









1 72 60 





2.2.2 Agarose-gel electrophoresis and gel extraction 
 
After the PCR reaction, the DNA needs to be separated from the rest of the PCR 
‘ingredients’ and, in order to do this, agarose-gel electrophoresis is used. 
DNA molecules carry a negative electric charge and, therefore, migrate towards 
the positive pole, when placed in an electric field. If the electrophoresis is performed in 
an agarose gel, the molecules can be separated according to their size, with optimal 
results depending on the gel concentration, for example, a 0.7% concentration allows 
the separation of fragments in a range from 0.8 to 12 kb, while a 2.0% is used to 
separate smaller fragments (0.05 to 2 kb). A DNA molecular weight marker is also 
loaded in the gel to allow a comparison with the sizes of these marker molecules. In 
order to visualize the result of the gel electrophoresis, the gel needs to be stained with 
ethidium bromide (EtBr); this compound binds to DNA molecules, by intercalating 
between adjacent base pairs, making them visible under UV light (Brown, 2001 and  
QIAEX II Handbook, 2008). 
 
The DNA fragments extracted from the gel can be purified using the QIAEX II 
system from QIAGEN that is based on solubilization of agarose using iodine and 
selective adsorption of nucleic acids onto QIAEX II silica-gel particles in the presence 
of chaotropic salt; according to the manufacturer’s instructions, QIAEX II silica-gel 
particles are added to the solubilized gel slice, the particles are collected by a brief 
centrifugation step, washed and the pure DNA fragment is eluted in Tris buffer or water 













The next step is to insert the purified DNA fragment into a vector, a circular 
DNA molecule that will act as a vehicle, transporting the gene into a host cell where it 
is going to be multiplied. As the cell divides into its progeny, a colony of identical cells 
is formed, all carrying the recombinant DNA.  
 
 






 TA Expression Kit from Invitrogen provides a 
cloning strategy for the direct insertion of Taq polymerase-amplified PCR products into 
a plasmid vector (Figure 16) because Taq polymerase has a nontemplate-dependent 
terminal transferase activity that adds a single deoxyadenosine (A) to the 3´ ends of 
PCR products and the pcDNA3.1/V5-His-TOPO
®
 has single, overhanging 3´ 
deoxythymidine (T) residues, allowing PCR inserts to ligate efficiently with the vector. 
The plasmid vector is supplied with a Topoisomerase I from Vaccinia virus covalently 
bound to it. This enzyme cleaves the phosphodiester bond after 5′-CCCTT and forms a 
covalent bond between a tyrosyl residue (Tyr-274) and the 3′ phosphate of the cleaved 
strand. The Taq polymerase-amplified PCR product is then ligated to the vector (Figure 
17), releasing the topoisomerase (pcDNA3.1/V5-His
© TOPO® TA Expression Kit, 
2004). 
 
Figure 16: Features of the pcDNA3.1/V5-His-TOPO© vector. The TOPO® Cloning Site is located base 





Figure 17: PCR product inserted in the the pcDNA3.1/V5-His-TOPO© vector with the topoisomerase 





Transformation is the term used to describe the uptake of a DNA molecule by a 
bacterial, fungal, animal or plant cell. The most used cells are the chemically competent 
Escherichia coli (E. coli) cells; a CaCl2 treatment enables the cells to uptake a bigger 




 TA Expression Kit from Invitrogen 
includes One Shot
®
 TOP10 chemically competent E. coli and the transformation is done 
according to the manufacturer’s instructions, regardless if the recombinant DNA comes 
from a TOPO
®
 Cloning reaction or from a rapid DNA ligation. The plates used are 
prepared from Luria-Bertani (LB) medium (25 g of LB broth per L of millipore water) 
with agarose (1,5g/100 mL of LB) and the intended antibiotic (50 µg of ampicilline or 
30 µg of kanamycin per mL of LB) (Brown, 2001). 
 
 
2.4 Colony/Orientation Check 
 
Although only the cells that have taken up the recombinant DNA grow due to 
their antibiotic resistance, there is a possibility that this DNA is not correct, either 
because the vector ligated on itself, or because the PCR construct was inserted in the 
wrong way (i.e. not in the desired orientation). Hence, a colony/orientation check is 
necessary. This is done by picking a few colonies with a sterile toothpick, resuspend 
them in 50 µL of water and use 1 µL of this as template for a PCR. The primers used are 
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described in Table 7 and the typical composition of the PCR mixture is represented on 
table 6. 
 
Table 6: Composition of the colony check reaction mixture.  
Component Volume (µL) 
H2O 29 
10x Super Taq PCR reaction buffer 2,5 
10x dNTPs 2 
25 µM Forward primer 1 
25 µM Reverse primer 1 
Template 1 
0,25 U/µL Super Taq 1 
 
 
Table 7: Sequence of the primers used to perform colony check on a pcDNA3.1/V5-His© TOPO® vector; 
fw – forward; rv – reverse. 
 
 
Table 8: Example of a PCR program used to perform colony check. 
Cycles Temperature (°C) Time (s) 





1 72 60 
1 4 ∞ 
 
After the PCR reaction, the mixtures are loaded in an agarose gel to check which 
ones have the expected length. The remainder of the resuspended colony mixture (49 
µL) are then inoculated into 5.5 mL of LB medium with either 11 µL of ampicillin or 14 
Primer Sequence of primer 
1045 (fw) 5’-GGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAG-3’ 
1046 (rv) 5’-GATGGCTGGCAACTAGAAGGCACAGTCGAAA-3’ 
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µL of kanamycin, depending on the vector used, and incubated overnight in a shaking 
incubator, at 37 °C, 200 rpm. 
 
 
2.5 Plasmid DNA purification 
 
The QIAprep Spin MiniPrep Kit from QIAGEN can be used to obtain high-
purity plasmid DNA by following a simple bind-wash-elute procedure (Figure 18) – 
bacterial cultures are lysed, centrifuged and then applied to the QIAprep spin column 
that contains a silica gel membrane where plasmid DNA adsorbs in the presence of a 
high concentration of chaotropic salt and, finally, impurities are washed away and pure 





Figure 18: QIAprep Spin MiniPrep plasmid DNA purification procedure (adapted from QIAprep 
MiniPrep Handbook, 2006). 
 
 
2.6 DNA sequencing 
 
The concentration of the plasmid DNA is then measured in a spectrophotometer 
(Pharmacia Biotech, GeneQuant II) and sent for sequencing at BaseClear, an accredited 
service laboratory for DNA-based research, quality assurance and forensics in Leiden, 
The Netherlands. Automated DNA sequencing determines the precise order of 
nucleotides and works in the following way: a primer is annealed on the single-stranded 
molecule to synthesize a new DNA strand; for this synthesis to occur, DNA polymerase 
needs the four deoxyribonucleotide triphosphates (dATP, dCTP, dGTP and dTTP); 
together with the dNTPs, a small amount of dideoxynucleotides (e.g. ddATP) is added 
to the reaction; in this way, the elongation is blocked because the ddNTPs lack the 3’-
hydroxyl group, resulting in a set of new chains, all of different lengths; the ddNTPs are 
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labelled with a different fluorolabel for each ddNTP (Figure 19), which allows the 
detector to recognize the last base of the chains. At BaseClear, the data analysis is 
performed automatically by PHRED, the international standard software for superior 




Figure 19: Automated DNA sequencing with fluorescently labeled dideoxynucleotides. (A) The chain 
termination reactions are carried out in a single tube, with each dideoxynucleotide labeled 
with a different fluorophore. In the automated sequencer, the bands in the electrophoresis gel 
move past a fluorescence detector, which identifies which dideoxynucleotide is present in 
each band. The information is passed to the imaging system. (B) The printout from an 
automated sequencer. The sequence is represented by a series of peaks, one for each 
nucleotide position. In this example, a green peak is an ‘A', blue is ‘C', black is ‘G', and red is 
‘T' (Brown, 1999). 
 
 




2.7 Insertion of the hFSHR with different tags in pIRES2-EGFP 
 
2.7.1 Site-directed mutagenesis on pIRES2-EGFP 
 
Site-directed mutagenesis is a method used to make precise alterations in gene 
sequences. The QuikChange site-directed mutagenesis kit from Stratagene is used to 
make point mutations and switch, delete or insert amino acids, by using PfuTurbo
®
 
DNA polymerase and a temperature cycler. This enzyme extends oligonucleotide 
primers that contain the desired mutation and are complementary to opposite strands of 
a vector, resulting in the generation of a mutated plasmid (Figure 20). After that, a 
treatment with 1µL of Dpn I endonuclease (20 u/µL), which target sequence is 5’-
Gm6ATC-3’, and incubation of the mixture at 37° for one hour, digests the parental 
DNA template and leaves the mutated DNA intact. In this way, and after cloning as 
explained before, only the cells that contain the mutated plasmid will grow, which is 
verified by DNA sequencing (Brown, 1999 and QuikChange
®
 Site-Directed 




Figure 20: Overview of the QuikChange® site-directed mutagenesis method (QuikChange® Site-Directed 
Mutagenesis Kit instruction manual, 2007). 
 
 
The parameters used to perform site-directed mutagenesis on the pIRES2-EGFP 
vector, in order to knock out the internal Not I site indicated in Figure 13, are described 
in Tables 9, 10 and 11. 
 
This technique has also been used to change to internal Bam HI site of the 




Table 9: Composition of the reaction mixture used to perform site-directed mutagenesis on the pIRES2-
EGFP vector. 
Component Volume (µL) 
H2O 33 
10x Pfu buffer + MgSO4 5 
10x dNTPs 4 
125 ng/µL Forward primer 2 
125 ng/µL Reverse primer 2 
25 ng/µL template 3 
Pfu enzyme 1 
 
 
Table 10: Sequence of the primers used to perform site-directed mutagenesis on the pIRES2-EGFP 
vector (2888 and 2889 – Not I site knocked out in bold) and to change to internal Bam HI site 




Table 11: PCR program used to perform site-directed mutagenesis on the pIRES2-EGFP vector. 
Cycles Temperature (°C) Time (s) 





1 72 60 
1 4 ∞ 
 
 
Primer Sequence of primer 
2888 (fw) 5’-AGCTGTACAAGTAAAGCGGACGCGACTCTAGATCATAATC-3’ 
2889 (rv) 5’-GATTATGATCTAGAGTCGCGTCCGCTTTACTTGTACAGCT-3’ 
2915 (fw) 5’-AGATATTTCAAGAACAAGAATTCATTCCCTGCCTAGC-3’ 
2916 (rv) 5’-GCTAGGCAGGGAATGAATTCTTGTTCTTGAAATATCT-3’ 
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2.7.2 Construction of pJC1, pJC2 and pJC3 
 
To facilitate the construction of the receptors, the signal sequences and the other 
tags were cloned into the MCS of the pIRES2-EGFP (Figure 13), by means of PCR 
reactions, resulting in the following vectors: 
 pJC1: pIRES2-EGFP with Bgl II – Prl s.s.- FLAG tag – Bam HI - Not I – Bgl II  
 pJC2 : pIRES2-EGFP with Bgl II – Prl s.s.- STREP tag – Bam HI - Not I – Bgl II 
 pJC3 : pIRES2-EGFP with Bgl II – hGPα s.s.- STREP tag – Bam HI - Not I – Bgl II 
 
 
2.7.2 Restriction endonuclease digestion 
 
Restriction endonucleases are enzymes that recognize a specific sequence on a 
DNA molecule, cleaving it. In this work we needed to insert the constructed hFSHRs 
into pJC1, pJC2 and pJC3, and for that, digestion with restriction endonucleases was 
needed. Table 12 shows the enzymes used and table 13 describes an example of the 
composition of a reaction mixture. 
 
Table 12: Restriction enzymes used in this work, the organism where they come from and the sequence 
they recognize. 
Restriction enzymes Organism Recognition sequence 
Bgl II Bacillus globigii AGATCT 
Bam HI Bacillus amyloliquefaciens GGATCC 
Eco RI Escherichia coli GAATTC 
Not I Nocardia otitidis-caviarum GCGGCCGC 
 
 
First, the wt hFSHR was cloned into the Bam HI/ Not I sites of pJC1, pJC2 and 
pJC3. Then, the hFSHR with the different tags were cut with Bam HI and Eco RI to be 
inserted in this portion of the vectors. Later, the hFSHR/cf-tail/RHO15 was cut with Eco 





For example, pJC1, pJC2 and pJC3 were cut with Bam HI and Not I, to allow the 
insertion of Bam HI/ Not I cut wt hFSHR: 
 
Table 13: Composition of a digestion reaction mixture – x is the volume that corresponds to 5 µg of 
plasmid in 50 µL of solution and y is the volume of H2O necessary to complete the total 
volume. 
Composition Volumes (µL) 




Bam HI 2,5 
Not I 2,5 
 
 
2.7.3 Rapid DNA ligation 
 
In order to ligate the cut fragments into pJC1, pJC2 and pJC3, the Rapid DNA 
Ligation Kit from Roche can be used, according to the manufacturer’s instructions. This 
kit is supplied with a T4 DNA Ligase, which has the function of repairing single-
stranded breaks or discontinuities in double-stranded DNA molecules or, in this case, 
joining together two individual fragments of double-stranded DNA; it forms a 
phosphodiester bond between the 3’ hydroxyl end of one nucleotide with the 5’ 
phosphate end of another. (Brown, 2001) 
 









2.8 Transient expression of constructed receptors in HEK 293-T cells 
 
In order to express the constructed receptors in HEK 293-T cells, a transfection 
system was used. Transfection is a technique that enables the incorporation of 
exogenous DNA into cells growing in culture; transcription in these cells allows the 
DNA to be expressed (Lewin, 2008). 
If the FSHR is expressed in a cell, and next stimulated with FSH, it will induce a 
signal-transduction pathway that leads to the activation of adenylyl cyclase and 
subsequent production of cAMP. In a ligand-induced cAMP production assay, it is 
possible to know how much hormone is necessary to activate the receptor. 
 
A technique to test if the receptors are expressed at the cell surface of the cells 
transfected is the enzyme-linked immunosorbent assay (ELISA). This is a direct binding 
assay for antibodies or antigens. There is an enzyme that is chemically linked to the 
antibody, in this case, an antibody recognizing the receptor or a tag attached to the 
receptor; the unlabeled antigen is attached to the wells of a plastic multi-well 
microplate. The labeled antibody binds to the unlabeled antigen and any unbound 
antibody and other proteins are washed away. This binding is detected by a reaction that 
converts a colorless substrate into a colored reaction product – the color change can be 
read in a spectrophotometer.  
 
 
2.9 Construction of mutated receptors 
 
According to the results obtained for the ligand-induced cAMP production assay 
and for the ELISA, the most optimal construct was chosen. On this construct some 
mutations were made through site-directed mutagenesis, as described on 2.7.1. The 








Table 14: Primers used for the site-directed mutagenesis; fw – forward; rv – reverse. 




3032 (fw) 5’-GGAATCTACCTGCTGCTCATTACATCAGTTGATATCCATACC-3’ 




3034 (fw) 5’-GACACCAGGATCGCCAAGTGCATGGCCATGCTCATCTTC-3’ 




3036 (fw) 5’-GCCTCCCTCAAGGTGCCCGTCATCACTGTGTCCAAAGC-3’ 
3037 (rv) 5’-GCTTTGGACACAGTGATGACGGGCACCTTGAGGGAGGC-3’ 
 
Insertion of the mutated constructs in pIRES2-EGFP, cloning and testing, 
























3. Results and Discussion 
 
3.1 Part 1 – Construction of hFSHRs with different signal sequences and 
different tags 
 
The FSHR constructs are composed of a signal sequence, one or more tags and 
the receptor itself, with its own C-terminal tail or with a catfish GnRHR C-terminal tail 
followed by the last 15 amino acids of human rhodopsin. 
The presence of different signal sequences and different tags will be tested to 
reveal which combination is the most advantageous in the way that enables the best 
FSHR expression in HEK 293-T cells, and which will be easiest to purify.  
The RHO15 sequence can act as purification tag as well. However, it is not only 
useful in purification due to the existence of 1D4, a monoclonal antibody (mAb) that 
recognizes the last 7 amino acids of human rhodopsin (TSQVAPA), but it is also 
necessary to get the receptor to be expressed in rod cells, since the RHO15 tag of 
rhodopsin is normally used as a quality control sequence for receptor trafficking to the 
rod outer segment, because this C-terminal portion is somehow recognized 
intracellularly in the rod cells. The last 7 amino acids of the human RHO15 sequence 
(STTVSKTATSQVAPA) are similar to the last 7 amino acids of the zebrafish RHO15 
sequence (KTEASSVSSSSVSPA) which led us to think that the human sequence can 
also be recognized in the rod cells of the zebrafish. 
In 2007, Thomas et al. discovered that hFSHR undergoes proteolytic clipping of 
its C-terminal tail – mature FSHR was not detected by a mAb directed to an epitope in 
its C-terminus. Conversely, it is known that the C-terminal of the catfish GnRHR is not 
clipped and can function to bind G proteins, leading to signal transduction (Navratil et 
al., 2006). 
 
Once all the FSHR constructs were prepared, they were tested for hFSH-induced 
cAMP production and cell surface expression in transiently transfected HEK 293-T 
cells. The aim was to find which construct had a signaling and expression behavior 




Looking at Figures 21 and 22 it is evident that a few constructs yielded receptor 
proteins that were not expressed at the cell surface. These results were expected for 
constructs without a FLAG-tag (17, 21, 29, 33 and 37, either A or B), since the ELISA 
in this experiment was performed with an antibody against the FLAG tag. However, 
constructs A5 and B5 (with a single FLAG-tag) were also not expressed at cell surface 
either, leading us to believe that a single tag would somehow impair the trafficking of 
the receptor towards the cell surface. 
The rest of the constructs seem to function in a proper way with expressions 




Figure 21: Cell surface expression of various wt-hFSHR constructs with different signal sequences and 





Figure 22: Cell surface expression of various hFSHR/cf-tail/RHO15 constructs with different signal 
sequences and tags, as determined by FLAG-tag ELISA. 
 
 The ligand-induced cAMP production revealed that the responsiveness of A/B-5, 
A/B-17 and A/B-33 to hFSH was decreased, as shown in Table 15. Table 15 presents 
the EC50 values of hFSH for the different receptors and when comparing these (ranging 
from 0.4821 to 170.3 ng/mL) with the expected value for the wt hFSHR (0.106 ng/mL; 
Vischer et al., 2003), one can conclude that their signaling is impaired. This was 
confirmed by their response curves (Figures 23-3/4, 24-1/2 and 25-1/2). 
 
Consistent with the ELISA results, receptors A/B-1, A/B-9, A/B-13, A/B-25 and 
A/B-41 seem to induce the production of cAMP (Figures 23-1/2/5/6/7/8, 24-5/6 and 25-
5/6). However, while the EC50 for the A constructs (i.e. wt-hFSHR constructs) are 
relatively close to the EC50 of the wt hFSHR, for the B constructs (i.e. hFSHR 
constructs with the cf-tail/RHO15 at their C-terminal end) these values are rather high. 
One possible explanation is that the normal FSHR C-terminal tail is somehow 
intimately involved in signaling given that in these constructs this portion is replaced by 






Table 15: Summary of the ligand-induced cAMP production in HEK 293-T cells transiently transfected 
with wt-hFSHR and hFSHR/cf-tail/RHO15 with different signal sequences and different tags. 







A1 - PRL-FLAG-FLAG 0.1160 B1 - PRL-FLAG-FLAG 29.33 
A5 - PRL-FLAG ND B5 - PRL-FLAG 0.4821 
A9 - PRL-FLAG-8xHis 0.1005 B9 - PRL-FLAG-8xHis 1.395 
A13 - PRL-FLAG-STREP 0.0749 B13 - PRL-FLAG-STREP 5.440 
A17 - PRL-STREP 0.7342 B17- PRL-STREP 35.08 
A21- PRL-STREP-8xHis 0.05656 B21- PRL-STREP-8xHis 2.590 
A25- PRL-STREP-FLAG 0.1794 B25- PRL-STREP-FLAG 5.683 
A29- PRL-STREP-STREP 0.1860 B29- PRL-STREP-STREP 3.567 
A33 - hGPα-STREP 3.828 B33- hGPα-STREP 170.3 
A37- hGPα-STREP-8xHis 0.1878 B37- hGPα-STREP-8xHis 6.447 
A41- hGPα-STREP-FLAG 0.5950 B41- hGPα-STREP-FLAG 4.013 
 
 
A general analysis of the response curves and the EC50 values leads to the 
conclusion that receptors A9 and B9 (PRL-FLAG-8xHis-wt-hFSHR and PRL-FLAG-
8xHis-hFSHR/cf-tail/RHO15, respectively) are the ones most reliably resembling the 
signaling and expression behavior of the wt hFSHR. Therefore, they were used for the 





















B1 - PRL-FLAG-FLAG-hFSHR/cf-tail/RHO 15































B5 - PRL-FLAG-hFSHR/cf-tail/RHO 15


































B9 - PRL-FLAG-8xHis-hFSHR/cf-tail/RHO 15






































B13 - PRL-FLAG-STREP-hFSHR/cf-tail/RHO 15

















































B17 - PRL-STREP-hFSHR/cf-tail/RHO 15


































B21 - PRL-STREP-8xHis-hFSHR/cf-tail/RHO 15

































B25 - PRL-STREP-FLAG-hFSHR/cf-tail/RHO 15






































B29 - PRL-STREP-STREP-hFSHR/cf-tail/RHO 15




















Figure 24: Ligand-induced cAMP production of: 1) A17; 2) B17; 3) A21; 4) B21; 5) A25; 6) B25; 7) 


























B33 - hGPα-STREP-hFSHR/cf-tail/RHO 15

















A37 - hGP α-STREP-8xHis-wt-hFSHR

















B37 - hGPα-STREP-8xHis-hFSHR/cf-tail/RHO 15


































B41 - hGPα-STREP-FLAG-hFSHR/cf-tail/RHO 15






























3.2 Part 2 – Construction of mutant hFSHRs 
 
The purpose of generating mutations in the receptors chosen in Part 1 was to 
create receptor constructs that are not capable of an FSH-induced production of cAMP, 
but that are well expressed at the cell surface or, in other words, produce receptor 
constructs that create inactive receptors. The proposed mutations are located in the 
transmembrane domain, which is known to be involved in signaling. 
 
Unfortunately, we came to the conclusion that the ELISA was not trustworthy 
since the procedure that has been used in this laboratory was optimized for another type 
of tag. Due to lack of time, it was not possible to develop a new protocol and so the 
experiment could not be repeated. Nonetheless, the results obtained are shown in 




Figure 26: Cell surface expression of FLAG-tagged wt-hFSHR with the different mutations, as 






Figure 27: Cell surface expression of FLAG-tagged hFSHR/cf-tail/RHO15 with the different mutations, 




Although the mutants with Arg
573





(3DM and 4DM) could not be tested because they contained sequence mistakes, it can 
be said that according to their EC50 values (Table 16) and their response curves (Figures 
28 and 29), one mutation is not enough to fully inactivate a receptor. But when two or 
three mutations are introduced, there is a drastic change in the receptor’s response and 
the signaling is either decreased or even completely impaired. However, this can be due 
to the absence of the receptor at the cell surface (which could not be trustworthy 
determined; see above) or to the fact that the receptor is indeed inactive. The only way 
to confirm one of these hypotheses is through an ELISA. In case this procedure could 
have been repeated and if it showed that for example the PRL-FLAG-8xHis-hFSHR/cf-






Val) was expressed at 
the cell surface, we would have created an inactive receptor construct that could be used 
for receptor expression in zebrafish rod cells, followed by protein purification from 
zebrafish eyes/rod cells, and next protein crystallization trials. The latter studies are 
extremely difficult to perform with GPCRs because one needs a single protein species 
as input material for crystallization trials. Each GPCR is thought to exist in different 
states of activation (i.e. a single protein species), even in the absence of ligand. 
Therefore such a purified batch of GPCRs may contain different protein species, each 
with a different level of intrinsic signalling activity. Introducing the above mentioned 
41 
 
mutations aimed at producing a batch of “silent receptor” proteins, each in the same 
state of receptor activation. 
 
Table 16: Summary of the ligand-induced cAMP production in HEK 293-T cells transiently transfected 
with PRL-FLAG-8xHis-wt-hFSHR and PRL-FLAG-8xHis-hFSHR/cf-tail/RHO15 with 
different mutations. ND – not detectable. NA – not applicable. 








































































A9 - 1SM - Ala419Thr














B9 - 2SM - Ala419Thr















A9 - 1 DM - Ala419Thr/Arg573Cys














B9 - 2DM - Ala419Thr/Arg573Cys















A9 - 1TM - Ala419Thr/Arg573Cys/Leu601Val














B9 - 2TM - Ala419Thr/Arg573Cys/Leu601Val















A9 - 5SM - Leu601Val

















A9 - 5DM - Leu601Val/Ala419Thr


















Figure 28: Ligand-induced cAMP production of mutant receptors when stimulated by hFSH: 1) 1SM; 2) 










B9 - 6SM - Leu601Val















B9 - 6DM - Leu601Val/Ala419Thr



















































B21 - Mock (no FLAG-tag)

















Figure 29: Ligand-induced cAMP production of:  1) 6SM; 2) 6DM; 3) A9; 4) B9 and 5) B21 (mock), 













4. Conclusion and Future Perspectives 
 
The studies described in this thesis had the objective of identifying a hFSHR 
construct that is expressed in HEK 293-T cells. Next, such a construct will be expressed 
in rod cells of the zebrafish to try to isolate this protein for purification. Some signal 
sequences and tags were used and mentioned here, but receptors with other such 
sequences, like Cystatin signal sequence, a T7-tag and MYC-tag, have also been 
constructed and await testing. 
Had the ELISA procedure worked well, we would possibly now have receptors 
ready to be used for the transgenesis studies. Because the receptors were constructed 
with a RHO15 sequence, the zebrafish will produce the mutant hFSHR as if it was 
rhodopsin and hopefully large quantities of protein will be present in their retinas.  
Several potential steps of purification will then to be tested to see which one is 
useful: 
 ROS purification as described by Liang et al., 2003; 
 Sucrose gradient (Hargrave, 1982); 
 Concanavalin A affinity chromatography (Litman, 1982); 
 Hydroxyapatite chromatography (Hong, 1982); 
 1D4 affinity (Molday and MacKenzie, 1983); 
 Solubilization with mild detergents and divalent cations. 
 
These purifications steps are expected to yield sufficient amount of protein that 
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6.1 Sequence of the human FSHR    
 
                                         Kozak         
    CGC XXX XXX GCC ACC ATG GCC CTG CTC CTG GTC TCT TT-> 
                        ATG GCC CTG CTC CTG GTC TCT TTG CTG GCA 
                         M   A   L   L   L   V   S   L   L   A     10 
                        tac cgg gac gag gac cag aga aac gac cgt 
 
 
TTC CTG AGC TTG GGC TCA GGAxTAC CCC TAC GAC GTG CCC GAC TAC GCC 
 F   L   S   L   G   S   G  xY   P   Y   D   V   P   D   Y   Ax    17 
aag gac tcg aac ccg agt cct atg ggg atg ctg cac ggg ctg atg cgg 
 
primer 2918 (hFSHR [ORF]-Fw primer; initial 69.4oC; Bam HI site; NNNNNN=GGA’TCC’CAC’CAC’CAC’CAC’CAT’CAT’CAT’CAC’GGC; 8 X HIS plus Glycine) 
primer 2919 (hFSHR [ORF]-Fw primer; initial 69.4oC; Bam HI site; NNNNNN=GGA’TCC’GAT’TAC’AAA’GAT’GAT’GAT’GAT’GTC’GGC; Flag tag plus Glycine) 
primer 2920 (hFSHR [ORF]-Fw primer; initial 69.4oC; Bam HI site; NNNNNN=GGA’TCC’TGG’TCC’CAT’CCC’CAG’TTT’GAG’AAG’GGC; Strep tag plus Glycine) 
CGCNNNNNN TGT CAT CAT CGG ATC TGT CAC TGC TCT AA-> 
primer 2917 (hFSHR [ORF]-Fw primer; initial 69.4oC; Bam HI site) 
CGCGGATCC TGT CAT CAT CGG ATC TGT CAC TGC TCT AA-> 
primer 1540 (hFSHR [ECD]-Fw primer; initial 66.6oC, later 78.6oC; Bam HI site) 
GGCGGATCC TGT CAT CAT CGG ATC TGT CAC TGC TCT AA-> 
TGT CAT CAT CGG ATC TGT CAC TGC TCT AAC AGG GTT TTT CTC TGC CAA 
xCx  H   H   R   I  xCx  H  xCx  S   N   R   V   F   L  xCx  Q     33 
aca gta gta gcc tag aca gtg ac gaga ttg tcc caa aaa gag acg gtt 
 
 
GAG AGC AAG GTG ACA GAG ATT CCT TCT GAC CTC CCG AGG AAT GCC ATT 
 E   S   K   V   T   E   I   P   S   D   L   P   R   N   A  xIx    49 
ctc tcg ttc cac tgt ctc taa gga aga ctg gag ggc tcc tta cgg taa 
 
     
XXXXXXGAAxCTG AGG TTT GTC CTC ACC AAG CTT CGA GTC ATC CAA AAA GGT GCA 
 Xβ1XxxE   L   R   F   V   Lx  T   K   L   R   V   I   Q   K   G   A     65 
XXXXXXctt gac tcc aaa cag gag tgg ttc gaa gct cag tag gtt ttt cca cgt 
 
 
XXXXXXTTT TCA GGA TTT GGG GAC CTG GAG AAA ATA GAG ATC TCT CAG AAT GAT 
 Xβ2Xx F   S   G   F   G   D   L  xE  xKx  I   E   I  xSx  Qx  N   D     81 
XXXXXXaaa agt cct aaa ccc ctg gac ctc ttt tat ctc tag aga gtc tta cta 
 
 
GTC TTG GAG GTG ATA GAG GCA GAT GTG TTC TCC AAC CTT CCC AAA TTA 
 V   L   E   V   I   E   A   D   V   F   S   N   L   P   K   L     97 
cag aac ctc cac tat ctc cgt cta cac aag agg ttg gaa ggg ttt aat 
 
 
XXXXXXCAT GAA ATT AGA ATT GAA AAG GCC AAC AAC CTG CTC TAC ATC AAC CCT 
 Xβ3XxxH   E   I   R   I   E   Kx  A   N   N   L   L   Y   I   N   P    113 
XXXXXXgta ctt taa tct taa ctt ttc cgg ttg ttg gac gag atg tag ttg gga 
 
 
XXXXXXGAG GCC TTC CAG AAC CTT CCC AAC CTT CAA TAT CTG TTA ATA TCC AAC 
 Xβ4Xx E   A   F   Q   N   L   P   N   L  xQ  xYx  L   L   I   S  xNx   129 
XXXXXXctc cgg aag gtc ttg gaa ggg ttg gaa gtt ata gac aat tat agg ttg 
 
 
ACA GGT ATT AAG CAC CTT CCA GAT GTT CAC AAG ATT CAT TCT CTC CAA 
 T   G   I   K   H   L   P   D   V   H   K   I   H   S   L   Q    145 
tgt cca taa ttc gtg gaa ggt cta caa gtg ttc taa gta aga gag gtt 
 
 
XXXXXXAAA GTT TTA CTT GAC ATT CAA GAT AAC ATA AAC ATC CAC ACA ATT GAA 
 Xβ5Xx K  xV   L   L  xDx  I   Q  xDx  N   I   N   I   H   T   I   E    161 





XXXXXXAGA AAT TCT TTC GTG GGG CTG AGC TTT GAA AGT GTG ATT CTA TGG CTG 
 Xβ6Xx R   N   S   F   V   G   L   S   F   E   S  xV   I   L   W   Lx   177 
XXXXXXtct tta aga aag cac ccc gac tcg aaa ctt tca cac taa gat acc gac 
 
 
     
XXXXXXAAT AAG AAT GGG ATT CAA GAA ATA CAC AAC TGT GCA TTC AAT GGA ACC 
 Xβ6Xx N   Kx  N   G   I   Q   E   I   H   N   C   A   F  xN   G   Tx   193 
XXXXXXtta ttc tta ccc taa gtt ctt tat gtg ttg aca cgt aag tta cct tgg 
                               
 
XXXXXXCAA CTA GAT GAG CTG AAT CTA AGC GAT AAT AAT AAT TTA GAA GAA TTG 
 Xβ7Xx Q   L  xD   E   L  xN   L   Sx  Dx  N   N   N   L   E   E   L    209 
XXXXXXgtt gat cta ctc gac tta gat tcg cta tta tta tta aat ctt ctt aac 
 
                                                    
XXXXXXCCT AAT GAT GTT TTC CAC GGA GCC TCT GGA CCA GTC ATT CTA GAT ATT 
 Xβ8Xx P   N   D   V   F   H   G   A   S   G   P  xV   I   L  xDx  Ix  225 
XXXXXXgga tta cta caa aag gtg cct cgg aga cct ggt cag taa gat cta taa 
 
  primer 1543 (Bam HI knock out-Fw; 72.0oC; overlap = 61.4oC) 
    AGA ACA AGG ATT CAT TCC CTG CCT AGC TAT GGC TT-> 
 primer 2915 (Bam HI to Eco RI; Fw; 69.5
o
C) 
TCA AGA ACA AGA ATT CAT TCC CTG CCT AGC-> 
XXXXXXTCA AGA ACA AGG ATC CAT TCC CTG CCT AGC TAT GGC TTA GAA AAT CTT 
 Xβ8XxxSx  Rx  T   R   I   H   S   L   P   S   Y   G   L   E   N   L   241 
XXXXXXagt tct tgt tcc tag gta agg gac gga tcg ata ccg aat ctt tta gaa 
AGT TCT TGT TCT TAA GTA AGG GAC GGA TCG-5’ 
 primer 2916 (Bam HI to Eco RI; Rv; 69.5
o
C) 
agt tct tgt tcc taa gta agg gac gg 
   primer 1542 (Bam HI knock out-Rv; 68.3oC; overlap = 61.4oC) 
 
                                                            ACT 
XXXXXXAAG AAG CTG AGG GCC AGG TCG ACT TAC AAC TTA AAA AAG CTG CCT ACT 
 Xβ9Xx K   K   L   R   A   R   Sx  T   Y   N   L   K   K   L   P   T   257 
XXXXXXttc ttc gac tcc cgg tcc agc tga atg ttg aat ttt ttc gac gga tga 
 
 
CTG GAA AAG CTT GTC GCC CTC ATG GAA GCC AGC CTC ACC TAT CCC AGC 
 L   E   K   L   V   A   L  xMx  E   A   S   L   T   Y   P   S   273 
gac ctt ttc gaa cag cgg gag tac ctt cgg tcg gag tgg ata ggg tcg 
 
 
CAT TGC TGT GCC TTT GCA AAC TGG AGA CGG CAA ATC TCT GAG CTT CAT 
 H  xCx xCx  A   F   A   N   W   R   R   Q   I   S   E   L   H   289 
gta acg aca cgg aaa cgt ttg acc tct gcc gtt tag aga ctc gaa gta 
 
 
CCA ATT TGC AAC AAA TCT ATT TTA AGG CAA GAA GTT GAT TAT ATG ACT 
 P   I  xCx xN   K   Sx  I   L   R   Q   E   V   D   Y  xMx  T   305 
ggt taa acg ttg ttt aga taa aat tcc gtt ctt caa cta ata tac tga 
 
 
CAG GCT AGG GGT CAG AGA TCC TCT CTG GCA GAA GAC AAT GAG TCC AGC 
 Q   A   R   G   Q   R   S   S   L   A   E   D  xN   E   Sx  S   321 
gtc cga tcc cca gtc tct agg aga gac cgt ctt ctg tta ctc agg tcg 
 
 
TAC AGC AGA GGA TTT GAC ATG ACG TAC ACT GAG TTT GAC TAT GAC TTA 
 Y   S   R   G   F   D  xMx  T   Y   T   E   F   D   Y   D   L   337 
atg tcg tct cct aaa ctg tac tgc atg tga ctc aaa ctg ata ctg aat 
 
 
TGC AAT GAA GTG GTT GAC GTG ACC TGC TCC CCT AAG CCA GAT GCA TTC 
xCx  N   E   V   V   D   V   T  xCx  S   P   K   P   D   A   F   353 





AAC CCA TGT GAA GAT ATC ATG GGG TAC AAC ATC CTC AGA GTC CTG ATA 
 N   P  xCx  E   D   I  xMx  G   Y   N   I   L   R  xV   L   Ix  369 
ttg ggt aca ctt cta tag tac ccc atg ttg tag gag tct cag gac tat 
 
 
TGG TTT ATC AGC ATC CTG GCC ATC ACT GGG AAC ATC ATA GTG CTA GTG 
xW   F   I   S   I   L   A   I   T   G   N   I   I   V   L   Vx  385 
acc aaa tag tcg tag gac cgg tag tga ccc ttg tag tat cac gat cac 
 
 
ATC CTA ACT ACC AGC CAA TAT AAA CTC ACA GTC CCC AGG TTC CTT ATG 
xI   L   Tx  T   S   Q   Y   K   L   T   V   P   R  xF   L   Mx  401 
tag gat tga tgg tcg gtt ata ttt gag tgt cag ggg tcc aag gaa tac 
TGC AAC CTG GCC TTT GCT GAT CTC TGC ATT GGA ATC TAC CTG CTG CTC 
xC   N   L   A   F   A   D   L   C   I   G   I   Y   L   L   Lx  417 
acg ttg gac cgg aaa cga cta gag acg taa cct tag atg gac gac gag 
 
 
ATT GCA TCA GTT GAT ATC CAT ACC AAG AGC CAA TAT CAC AAC TAT GCC 
xI   A   S   Vx  D   I   H   T   K   S   Q   Y   H   N   Y   A   433 
taa cgt agt caa cta tag gta tgg ttc tcg gtt ata gtg ttg ata cgg 
 
 
ATT GAC TGG CAA ACT GGG GCA GGC TGT GAT GCT GCT GGC TTT TTC ACT 
 I   D   W   Q   T   G   A   G   C  xD   A   A   G   F   F   Tx  449 
taa ctg acc gtt tga ccc cgt ccg aca cta cga cga ccg aaa aag tga 
 
 
GTC TTT GCC AGT GAG CTG TCA GTC TAC ACT CTG ACA GCT ATC ACC TTG 
xV   F   A   S   E   L   S   V   Y   T   L   T   A   I   T   Lx  465 
cag aaa cgg tca ctc gac agt cag atg tga gac tgt cga tag tgg aac 
 
 
GAA AGA TGG CAT ACC ATC ACG CAT GCC ATG CAG CTG GAC TGC AAG GTG 
 E   R   W   H   T   I   T   H   A   M   Q   L   D   C   K   V   481 
ctt tct acc gta tgg tag tgc gta cgg tac gtc gac ctg acg ttc cac 
 
 
CAG CTC CGC CAT GCT GCC AGT GTC ATG GTG ATG GGC TGG ATT TTT GCT 
 Q   L   R   H  xA   A   S   V   M   V   M   G   W   I   F   Ax  497 
gtc gag gcg gta cga cgg tca cag tac cac tac ccg acc taa aaa cga 
 
 
TTT GCA GCT GCC CTC TTT CCC ATC TTT GGC ATC AGC AGC TAC ATG AAG 
xF   A   A   A   L   F   P   I   F   G   Ix  S   S   Y   M   K   513 
aaa cgt cga cgg gag aaa ggg tag aaa ccg tag tcg tcg atg tac ttc 
 
 
GTG AGC ATC TGC CTG CCC ATG GAT ATT GAC AGC CCT TTG TCA CAG CTG 
 V   S   I   C   L   P   M   D   I   D   S   P   L   S   Q  xLx  529 
cac tcg tag acg gac ggg tac cta taa cgt tcg gga aac agt gtc gac 
 
 
TAT GTC ATG TCC CTC CTT GTG CTC AAT GTC CTG GCC TTT GTG GTC ATC 
xY   V   M   S   L   L   V   L   N   V   L   A   F   V   V   Ix  545 
ata cag tac agg gag gaa cac gag tta cag gac cgg aaa cac cag tag 
 
 
TGT GGC TGC TAT ATC CAC ATC TAC CTC ACA GTG CGG AAC CCC AAC ATC 
xC   G   C   Y   Ix  H   I   Y   L   T   V   R   N   P   N   I   561 
aca ccg acg ata tag gtg tag atg gag tgt cac gcc ttg ggg ttg tag 
 
 
GTG TCC TCC TCT AGT GAC ACC AGG ATC GCC AAG CGC ATG GCC ATG CTC 
 V   S   S   S   S   D   T   R   I   A   K   R  xM   A   M   Lx  577 





ATC TTC ACT GAC TTC CTC TGC ATG GCA CCC ATT TCT TTC TTT GCC ATT 
xI   F   T   D   F   L   C   M   A   P   I   S   F   F   A   Ix  593 
tag aag tga ctg aag gag acg tac cgt ggg taa aga aag aaa cgg taa 
 
 
TCT GCC TCC CTC AAG GTG CCC CTC ATC ACT GTG TCC AAA GCA AAG ATT 
xS   A   S   Lx  K   V   P   L   I   T   V   S   K   A   K  xIx  609 
aga cgg agg gag ttc cac ggg gag tag tga cac agg ttt cgt ttc taa 
 
 
CTG CTG GTT CTG TTT CAC CCC ATC AAC TCC TGT GCC AAC CCC TTC CTC 
xL   L   V   L   F   H   P   I   N   S   C   A   N   P   F   Lx  625 
gac gac caa gac aaa gtg ggg tag ttg agg aca cgg ttg ggg aag gag 
 
TAT GCC ATC TTT ACC AAA AAC TTT CGC AGA GAT TTC TTC ATT CTG CTG  
xY   A   I   F   Tx  K   N   F   R   R   D   F   F   I   L  xLx  641 
ata cgg tag aaa tgg ttt ttg aaa gcg tct cta aag aag taa gac gac 
 
 
AGC AAG TGT GGC TGC TAT GAA ATG CAA GCC CAA ATT TAT AGG ACA GAA 
 S   K   C   G   C   Y   E   M   Q   A   Q   I   Y   R   Tx  E   657 
tcg ttc aca ccg acg ata ctt tac gtt cgg gtt taa ata tcc tgt ctt 
 
 
ACT TCA TCC ACT GTC CAC AAC ACC CAT CCA AGG AAT GGC CAC TGC TCT 
 T   S   S   T   V   H   N   T   H   P   R   N   G   H   C   S   673 
tga agt agg tga cag gtg ttg tgg gta ggt tcc tta ccg gtg acg aga 
 
 
TCA GCT CCC AGA GTC ACC AGT GGT TCC ACT TAC ATA CTT GTC CCT CTA 
 S   A   P   R   V   T   S   G   S   T   Y   I   L   V   P   L   689 
agt cga ggg tct cag tgg tca cca agg tga atg tat gaa cag gga gat 
                                    <-A ATG TAT GAA CAG GGA GAT 
                                                    <-g gga gat 
 
 
AGT CAT TTA GCC CAA AAC[TGA] 
 S   H   L   A   Q   N  
tca gta aat cgg gtt ttg 
TCA GTA AAT CGG GTT TTG ACT CGCCGGCG GC-5’ 
primer 2921 (hFSHR-Rv primer; initial 69.9oC; Not I site) 
tca gta aat cgg gtt ttg ACT CGCCGGCG T 
















6.2 Prediction of a signal peptide cleavage site 
 





>Sequence              length = 38 
# Measure  Position  Value  Cutoff  signal peptide? 
  max. C    31       0.780   0.32   YES 
  max. Y    31       0.788   0.33   YES 
  max. S    19       0.988   0.87   YES 
  mean S     1-30    0.680   0.48   YES 
       D     1-30    0.734   0.43   YES 





Prediction: Signal peptide 
Signal peptide probability: 0.994 
Signal anchor probability: 0.005 



























Stock media/solutions for cell culturing (stored at 4°C, used at 37°C) 
 
Materials: 
- Culture medium:  
500 mL Dulbecco’s Modified Eagle’s medium (DMEM) {Gibco 41965-039} 
50 mL Fetal Bovine serum (Gibco 10270-106 /South American)) 
5 mL antibiotic-Antimyotic (100x) {Gibco 15240-062} 
5 mL L-Glutamin (100x) {Gibco 25030-024} 
- Wash-medium: 500 mL DMEM 
 
- Trypsin/EDTA {Gibco 25300-054} 
- D-PBS {Sigma D-8537} 
 
 
6.4.2 PEI-Transfection + receptor expression 
 
• Day 1: Seed cells  
 
1. Place PBS, Culture medium and Trypsin/EDTA at 37°C. 
2. Use HEK 293-T cells at 60-80% confluence in a 75 cm culture flask. Aspirate 
culture medium and gently rinse the cells with 3 mL PBS. 
3. Resuspend the cells in 1 mL trypsin/EDTA for maximal 5 min, add 11 mL culture 
medium, resuspend and transfer suspension to 50 ml-tube 
4. Mix 10 µL with 10 µL trypan-blue, count cells in 25 (inner) squares. 
  (#cells/25) x 25 x 2 x 10^4 = n cells/ml stock 
5. Dilute suspension with culture medium so that 1 mL contains 375000 cells. 
6. Seed 8 ml (=3 x 10^6cells) in a 10 cm-costar culture dish {430167}and incubate 




• Day 2: PEI-transfection 
 
(Polyethylenimine; Polysciences Inc. Warrington PA, Cat.nr. 23966) with pCre/b-Gal 
Plasmid (our Glyc. Stock 6564) and receptor /pcDNA3.1 expression vector. 
 
1. Place wash-medium and PBS at 37°C. 
2. Prepare 800 µL transfection mix for each dish in 14 mL-transfection tubes {Falcon 
polystyrene round-bottom tubes 2057, 81780 Emergo): 
- 5 µg pCre/β-Gal 
  - 500 ng receptor/pcDNA3.1  
  - 33 µg PEI (1 µg/µL, stored frozen) 
  - Fill up to 800 µL with sterile double-distilled water 
   - Mix gently; incubate this transfection Mix for at least 15 min. 
3. Meanwhile: aspirate culture medium and wash cells gently once with 3 mL PBS. 
4. Add first 8 mL Wash-Medium and then 800 µL Transfection Mix to each dish. 
Resuspend the transfection Mix once (carefully) and add droplets homogenously. 
5. Incubate for 3 hours at 37°C under 5% CO2. 
6. Aspirate transfection medium. 
7. Rinse cells carefully 2 times with 3 mL PBS. 
8. Add 8 mL culture medium and incubate overnight at 37°C under 5% CO2. 
 
 
• Day 3: Transfer transfected HEK 293-T cells to 24 and 96-wells plates. 
 
1. Place culture medium, D-PBS and trypsin/EDTA at 37°C. 
2. Aspirate culture medium and wash cells gently with PBS. 
3. Resuspend cells in 1 mL trypsin/EDTA for maximal 5min and bring the 1 mL cells 
in ‘X’ mL culture medium (volume X is dependent of amount of stimulations). 
4. Resuspend cells with a repeat pipet. 
5. Functional assay: Fill enough wells of a 96-well Costar plate (Corning Costar – 
3595} with 200 µL/well 




7. ELISA: 5 mL Mock cells in 6 cm Petri dish* (for pre-absorption) 
 
* Wells must be coated before use with poly-D-Lysine {Sigma P-7280} before cells are 
applied; 
 -750 µL/ 6cm dish; 250 µL/ 24-wells-plate 
 -10 min at room temperature 
 -aspirate poly-D-Lysine 
 -rinse with 0.5 mL sterile double distilled water 
 -aspirate water, “store” at room temperature  
Poly-D-Lysine:  
 - Dissolve 5 mg in 50 mL sterile double distilled water (0.1 mg/mL) 
 - Filter through Millipore (0.22 µm) 
 - Store aliquots at -20°C. 
 
 
6.4.3 Ligand Stimulation + ELISA 
 
• Day 4 
 
Stimulation of transfected HEK-T 293 cells with ligands. 
 
Lysis buffer: 0.25 M Tris/HCl pH 7.8 
  0.5% NP 40 (0.5 mL/100 mL) 
 
1. Prepare Stimulation medium: 
# DMEM (HEPES-modified; {Sigma D-6171}) 
# 0.1 mM IBMX (Sigma I-5879; Stock = 10 mM in DMSO) (=100x dil) 
# 0.01% BSA (Sigma A-9647)  (=10 mg/100 mL) 
2. Make serial dilutions of the ligand in stimulation medium. 
3. Aspirate culture medium from cells in 96-wells plates. 
4. Add 25 µL stimulation medium containing the desired (increasing) ligand 
 concentration* to each well. Add stimulation medium without ligand (-) or 
61 
 
 containing 10 µM Forskolin (+) (500 x from stock Sigma F-6886) in order to 
 measure respectively basal and standard stimulation. 
5. Incubate for 6 hours at 37°C under 5% CO2. 
6. Aspirate stimulation medium and freeze cells at -80°C for 15 min. 
7. Thaw cells (15 min at 37°C) and add 50 µL lysis buffer to each well.  
8. Vortex the plates gently and freeze overnight at -20°C. 
 
* Prepare from the desired ligands the following concentrations in stimulation buffer by 
serial dilutions. Calculate the volume of ligand and stimulation buffer needed for each 
dilution step. Note that you’ll need at least 3 x 25 µL of each concentration (for 1 
construct). 
 





























- PBS (10 mM Na-phosphate pH 7.0; 150 mM NaCl) 
- 4% Formaldehyde: make out of 37% (Merck 1.04003.2500) 
- TBS (30 mL 5M NaCl, 50 mL 1 M Tris-HCl pH 7.5, filled up to 1 liter with 
double distilled water. 
- Blocking buffer (0.1 M NaHCO3, pH 8.6 adjusted with NaOH, 1% 
Milkpowder) 





 Antibody: Anti-FLAG high affinity; rat monoclonal antibody; 50 µg in 0.5 
ml double distilled water (stock) aliquots in -20°C. 
 
1. Prepare 4% fresh FA (out of 37%). 
2. Aspirate medium. 
3. Wash with 0.5 mL pre-warmed TBS. 
4. Fixate with 0.5 mL/well 4% PFA, 30 min, room temperature. 
5. Prepare blocking buffer (0.1 M NaHCO3 pH 8.6 adjusted with NaOH, 1% 
Milkpowder) = 0.5 gr milk powder + 50 mL NaHCO3. 
6. Aspirate FA. 
7. Wash 3 times with 0.5 mL TBS. 
8. Block at least 4 h (at room temperature) on a shaker with 0.5 mL blocking 
buffer/well. 
9. 1.5 h before the blocking stops: 
- Preabsorption antiserum: 
10. Use spare HEK 293-T cells in a 6 cm dish. 
11. Aspirate medium. 
12. Wash once with 5 mL pre-warmed TBS. 
13. 30 min fixation at room temperature with 4% PFA. 
14. Wash 3 times with 5 mL TBS. 
15. Dilute 1
st
 antibody (anti-FLAG) 200 x in TBS/0.1%BSA (0.01 gr BSA/10 mL) 
16. Incubate 5 mL diluted antibodies on fixated, washed HEK 293-T cells (‘Mock”) 
for 1 h at 37 °C. (5 mL = enough for 21 samples) 
-------------------------------- 
17. 5 min before preabsorption stops: 
18. Aspirate blocking buffer from wells. 
19. Add the preabsorbed 1
st
 Antibody (anti-FLAG) = 0.23 mL/well 







6.4.4 β-galactosidase-assay + ELISA 
 
Substrate Buffer:  
- 100 mM sodium phosphate, pH 7.5 
 - 10 mM KCl 
 - 1 mM MgSO4 
 - 50 mM β-Mercapto-ethanol (add just prior to use; 1 M Stock) 
   
Prepare as follows: 
 - Solution 1: 27.6 gr/L NaH2PO4.H2O (M=137.99) 
 - Solution 2: 35.59 gr/L Na2HPO4.H2O (M=177.99) 
 
Make a 200 mM sodium phosphate solution: ≈ 16 mL solution 1 + ≈ 84 mL solution 2, 
adjust to pH 7.5 using these solutions. 
 
Take 100 mL of this solution and add 2 mL KCL (1M), 200 µL MgSO4 (1M) and 98 
mL sterile double distilled water (do not autoclave!  precipitation!). 
 
Substrate: 4 mg onpg /mL (Sigma N-1127) in 100 mM sodium phosphate buffer 
(without KCl and MgSO4!).Aliquots can be stored in -20. 
   
1. Pool substrate (50 µL/well) and substrate buffer (110 µL/well). 
2. So add 160 µL of the mix to each well. 
3. Incubate plates at room temperature depending on how long coloration develops. 
4. Measure OD 405 nm (OD 655 nm as a reference) in a 96-well-microplate-reader, 
until Forskolin ≈ 1.0. 
5. Divide all values by the forskolin value (use PrismGraph 4.0) after correction with 
Mock. 












 Antibody: anti-rat IgG (whole molecule) peroxidase conjugate (Sigma A-
 9037) (aliquots 16 µL) 
- TMB (Sigma # T-8665) 
- 0.5 M Sulphoric Acid (H2SO4, M=98.08 gr/mol; 1 liter = 1.84 gram) 
 




3. Wash 3 times with 0.5 mL TBS. 
4. Dilute 2
nd
 Antibody 1: 500 in fresh blocking buffer (0.1 gr milk /10 mL NaHCO3) 
and add 0.25 mL to cells. 




7. Wash 3 times with 0.5 mL TBS. 
8. Add 0.4 mL TMB. 
9. Stain on shaker at room temperature for 10-30 min. Stop reaction when a clear 
difference is seen between mock and FLAG-tagged receptors. 
10. Stop reaction with 0.2 mL 0.5 M Sulphoric acid. 
11. Transfer 0.1 mL to 96-wells plate (duplo). 
12. Measure OD at 450 nm (use 655 nm as reference; Dual wavelength). 
13. Calculate and make a drawing of the expression-levels (in Excel). 
